Skip to main content

Full Schedule

Full Schedule

  • Wednesday, July 16, 2025
  • 8:15 AM - 8:30 AM HST
    RP2D Determination of Bleximenib in Combination With VEN+AZA: Phase 1B Study in ND & R/R AML With KMT2A/NPM1 Alterations
  • 8:15 AM - 11:05 AM HST
    Acute Lymphoblastic Leukemia (ALL)
  • 8:30 AM - 8:45 AM HST
    Efficacy/Safety of the BTK Degrader NX-5948 in Patients With Chronic Lymphocytic Leukemia: An Ongoing Phase 1A/B Study
  • 8:45 AM - 9:00 AM HST
    Acute Lymphoblastic Leukemia (ALL)
  • 9:00 AM - 9:15 AM HST
    Acute Lymphoblastic Leukemia (ALL)
  • 9:15 AM - 9:30 AM HST
    Acute Lymphoblastic Leukemia (ALL)
  • 9:30 AM - 9:45 AM HST
    Acute Lymphoblastic Leukemia (ALL)
  • 10:20 AM - 10:35 AM HST
    Acute Lymphoblastic Leukemia (ALL) - Chemotherapy Options for Upfront Management of ALL
  • 10:35 AM - 10:50 AM HST
    Acute Lymphoblastic Leukemia (ALL) - Chemotherapy Options for Upfront Management of ALL
  • 10:50 AM - 11:05 AM HST
    Acute Lymphoblastic Leukemia (ALL) - Chemotherapy Options for Upfront Management of ALL
  • 11:20 AM - 11:35 AM HST
    Myeloproliferative Neoplasms (MPN)
  • 11:35 AM - 11:50 AM HST
    Myeloproliferative Neoplasms (MPN)
  • 11:50 AM - 12:05 PM HST
    Myeloproliferative Neoplasms (MPN)
  • 12:05 PM - 12:20 PM HST
    Myeloproliferative Neoplasms (MPN)
  • 3:00 PM - 4:00 PM HST
    Meet the Experts
  • 4:00 PM - 5:00 PM HST
    Meet the Experts